IRCT20200708048051N1尚未招募3 期
Assessment of the effect of rivaroxaban as Adjuvant Treatment for improvement of Idiopathic Sudden Sensorineural Hearing Loss
Rasht University of Medical Sciences0 个研究点目标入组 140 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 140
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 65 years（—）
- 性别
- All
入选标准
- •Patients with a unilateral sudden sensory hearing loss
- •Refer to the hospital in less than 5 days from the onset of symptoms
- •Hearing loss of = 30 dB at least 3 consecutive frequencies in the audiometery.
排除标准
- •Patients with a history of hearing loss, trauma to the ear, active ear infection, congenital cochlear disease
- •Use of ototoxic drugs, anticoagulants, anticonvulsants.
- •Cardiovascular disease, coagulation disorders, and diabetes.
- •Retro cochlear lesions
- •Severe renal and hepatic impairment (Cr clearance less than 15)
- •People with neoplasms who have not been treated or are being treated with chemotherapy or radiotherapy.
- •pregnancy and breastfeeding
- •Patients with history of autoimmune disorder
- •Patients with platelet count disorder (less than 150,000)
研究者
相似试验
招募中
2 期
Treatment with rivaroxaban compared with warfarin in patients with acute coronary syndromeAcute coronary syndrome.Other acute ischemic heart diseasesIRCT20210614051574N9Esfahan University of Medical Sciences60
招募中
2 期
Assessment of the impact of Rivaroxaban in peripheral artery disease (PAD) of the lower extremitiesIRCT20231117060086N1Ahvaz University of Medical Sciences112
招募中
2 期
Evaluating the efficacy and safety of rivaroxaban comparing to warfarin in patients with chronic thromboembolic pulmonary hypertension (CTEPH) following endartrectomy surgeryChronic Thrombo Embolic Pulmonary Hypertension(CTEPH).Chronic Thromboembolic Pulmonary Hypertension.I27. 24IRCT20151227025726N22Shahid Beheshti University of Medical Sciences96
招募中
2 期
Efficiency of rivaroxaban and enoxaparin in the prevention of venous thromboembolic eventsSpinal fusion.Osseous stenosis of neural canalM99.3IRCT20120527009878N16Tabriz University of Medical Sciences60
进行中（未招募）
1 期
A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer ParticipantsVenous thromboembolism (VTE)MedDRA version: 19.0 Level: LLT Classification code 10066899 Term: Venous thromboembolism System Organ Class: 100000004866EUCTR2015-001630-21-GBJanssen-Cilag International N.V.841